Tiziana Life Sciences PLC TLSA Open Tiziana Life Sciences PLC in new tab
Tiziana Life Sciences PLC Analysis (TLSA)
Is Tiziana Life Sciences PLC a good investment? Tiziana Life Sciences PLC (TLSA) is currently trading at 1.25 USD.
Earnings Schedule: Tiziana Life Sciences PLC is expected to release its next earnings report on April 8, 2026. The market consensus estimate for Forward EPS is -0.20.
Investor FAQ
Does Tiziana Life Sciences PLC pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tiziana Life Sciences PLC?
Tiziana Life Sciences PLC is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be April 8, 2026. The company currently has a trailing EPS of -0.12.
Company Profile
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Dividends
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 29, 2019 | 2.000000 |
| July 31, 2020 | 2.500000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion